Medroloan II SUIK and Romosozumab-aqqg
Determining the interaction of Medroloan II SUIK and Romosozumab-aqqg and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration of romosozumab with bisphosphonates, denosumab, angiogenesis inhibitors, or corticosteroids may increase the risk of developing osteonecrosis of the jaw (ONJ). The condition can occur spontaneously and is generally associated with tooth extraction and/or local infection with delayed healing. Other risk factors for ONJ include cancer, chemotherapy, radiotherapy to the head and neck, poor oral hygiene, preexisting dental disease or infection, anemia, and coagulopathy. MANAGEMENT: Caution is advised when romosozumab is used with other agents that are also associated with osteonecrosis of the jaw. A routine oral examination should be performed by the prescriber prior to initiation of romosozumab treatment. For patients requiring invasive dental procedures, clinical judgment and risk-benefit assessment should guide the management plan of each patient based on their clinical circumstances. Patients should be advised to seek medical attention if they experience signs and symptoms of ONJ, such as: pain in the mouth, teeth, or jaw; swelling or sores inside the mouth; numbness or a feeling of heaviness in the jaw; loosening of a tooth; or exposure of bone in the jaw. Those who are suspected of having or who develop ONJ during romosozumab therapy should receive care by a dentist or an oral surgeon. In these patients, dental surgery to treat ONJ may exacerbate the condition. Discontinuation of romosozumab should be considered based on benefit-risk assessment. References "Product Information. Evenity (romosozumab)." Amgen USA, Thousand Oaks, CA.
Professional:MONITOR: Coadministration of romosozumab with bisphosphonates, denosumab, angiogenesis inhibitors, or corticosteroids may increase the risk of developing osteonecrosis of the jaw (ONJ). The condition can occur spontaneously and is generally associated with tooth extraction and/or local infection with delayed healing. Other risk factors for ONJ include cancer, chemotherapy, radiotherapy to the head and neck, poor oral hygiene, preexisting dental disease or infection, anemia, and coagulopathy.
MANAGEMENT: Caution is advised when romosozumab is used with other agents that are also associated with osteonecrosis of the jaw. A routine oral examination should be performed by the prescriber prior to initiation of romosozumab treatment. For patients requiring invasive dental procedures, clinical judgment and risk-benefit assessment should guide the management plan of each patient based on their clinical circumstances. Patients should be advised to seek medical attention if they experience signs and symptoms of ONJ, such as: pain in the mouth, teeth, or jaw; swelling or sores inside the mouth; numbness or a feeling of heaviness in the jaw; loosening of a tooth; or exposure of bone in the jaw. Those who are suspected of having or who develop ONJ during romosozumab therapy should receive care by a dentist or an oral surgeon. In these patients, dental surgery to treat ONJ may exacerbate the condition. Discontinuation of romosozumab should be considered based on benefit-risk assessment.
- "Product Information. Evenity (romosozumab)." Amgen USA, Thousand Oaks, CA.
Generic Name: methylprednisolone
Brand name: Medrol, Medrol Dosepak, MethylPREDNISolone Dose Pack, A-methapred, Depo-Medrol, Solu-Medrol
Synonyms: Methylprednisolone, MethylPREDNISolone
Generic Name: romosozumab
Brand name: Evenity
Synonyms: Romosozumab
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Medroloan II SUIK-Ropinirole
- Medroloan II SUIK-Ropinirole Extended-Release Tablets
- Medroloan II SUIK-Ropinirole Hydrochloride
- Medroloan II SUIK-Ropinirole Tablets
- Medroloan II SUIK-Ropivacaine
- Medroloan II SUIK-Ropivacaine Hydrochloride
- Romosozumab-aqqg-Medroloan SUIK
- Romosozumab-aqqg-Medrox (Capsaicin and Menthol Patch)
- Romosozumab-aqqg-Medrox (Methyl Salicylate, Menthol, and Capsaicin Cream and Ointment)
- Romosozumab-aqqg-Medrox (Methyl Salicylate, Menthol, and Capsaicin Patch)
- Romosozumab-aqqg-Medrox-Rx
- Romosozumab-aqqg-Medrox-Rx Ointment